(Somehow I doubt this will help us as the end user....we)
Express Scripts buying Medco for $29.1B
By LINDA A. JOHNSON, AP Business Writer
Thursday, July 21, 2011
In this photo provided by Express Scripts, David Snow, CEO of Medco Health Solutions, left, and George Paz, CEO of Express Scripts, shake hands Thursday July 21, 2011, after conclusion of negotiations to merge the two companies. The new company will be known as Express Scripts with headquarters in St. Louis, Mo.
IMAGES
View Larger Images
MORE NEWS
Prospects for a debt breakthrough seem dim 07.23.11
Norway bomb suspect bought 6 tons of fertilizer 07.23.11
Gunman's background puzzles police in Norway 07.23.11
(07-21) 15:19 PDT (AP) --
The top two U.S. companies managing prescription drug benefits are uniting in a $29.1 billion deal they say will help achieve key goals of the health care overhaul: reining in costs and improving patients' health.
Express Scripts Inc. announced an agreement Thursday to buy rival Medco Health Solutions Inc. Together, they would handle the prescriptions of about 135 million people, more than one in three Americans.
That will give them even more clout in demanding discounts from drugmakers, who are dealing with falling or stagnant revenue as an unprecedented number of blockbuster drugs taken daily by millions is getting cheaper generic competition.
Pharmacy benefit managers process mail-order prescriptions and handle bills for prescriptions filled at retail pharmacies, acting as middlemen between employers offering prescription drug benefits and drugmakers. They also hold down costs by extracting discounts and rebates from drugmakers, using tiered copayments that nudge patients to buy generics or the lowest-cost brand names, and reminding patients to take medicines as scheduled to limit costly complications.
Together, Express Scripts and Medco handled more than 1.7 billion prescriptions in 2010 and reported almost $110 billion in revenue, although Medco recently lost several contracts covering millions of people. They have razor-thin profit margins.
"The deal strategically makes sense because in this business, scale matters," said Les Funtleyder, health care portfolio manager for Miller Tabak.
The combined company may be able to wring even lower prices from drugmakers. Their trade group, Pharmaceutical Research and Manufacturers of America, said it had no position on the deal.
It's unclear whether patients, or just employers and health plans, will see the future savings. But patients likely will face stricter rules requiring more use of generics and of mail order services for drugs for chronic conditions, and more programs aimed at ensuring they're on the best medicine for them.
Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2011/07/21/national/a033954D99.DTL#ixzz1SwXWLOrU
| 
